Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$61.35−1.58 (-2.51%)
Close on Nov 17, 2026Market cap $125.41BP/E 13.6Yield 4.06%
Bristol Myers Squibb total assets
Total assets on the balance sheet at the end of each period.
Bristol Myers Squibb's total assets was $88.77B at Sep 30, 2026. For fiscal 2025 it was $90.04B, down 2.8% from the year before. Over ten years it grew 11.0% a year on average. The highest annual figure on record is $129.94B in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.04B | -2.8% |
| FY2024 | Dec 31, 2024 | $92.60B | -2.7% |
| FY2023 | Dec 31, 2023 | $95.16B | -1.7% |
| FY2022 | Dec 31, 2022 | $96.82B | -11.4% |
| FY2021 | Dec 31, 2021 | $109.31B | -7.7% |
| FY2020 | Dec 31, 2020 | $118.48B | -8.8% |
| FY2019 | Dec 31, 2019 | $129.94B | +271.4% |
| FY2018 | Dec 31, 2018 | $34.99B | +4.3% |
| FY2017 | Dec 31, 2017 | $33.55B | -0.5% |
| FY2016 | Dec 31, 2016 | $33.71B | +6.2% |
| FY2015 | Dec 31, 2015 | $31.75B | -5.9% |
| FY2014 | Dec 31, 2014 | $33.75B | -12.5% |
| FY2013 | Dec 31, 2013 | $38.59B | +7.5% |
| FY2012 | Dec 31, 2012 | $35.90B | +8.9% |
| FY2011 | Dec 31, 2011 | $32.97B | +6.1% |
| FY2010 | Dec 31, 2010 | $31.08B | +0.2% |
| FY2009 | Dec 31, 2009 | $31.01B | +5.2% |
| FY2008 | Dec 31, 2008 | $29.49B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $88.77B | -8.4% |
| Q2 FY2026 | Jun 30, 2026 | $87.63B | -7.4% |
| Q1 FY2026 | Mar 31, 2026 | $86.48B | -6.4% |
| Q4 FY2025 | Dec 31, 2025 | $90.04B | -2.8% |
| Q3 FY2025 | Sep 30, 2025 | $96.89B | +3.4% |
| Q2 FY2025 | Jun 30, 2025 | $94.68B | +0.0% |
| Q1 FY2025 | Mar 31, 2025 | $92.43B | -6.7% |
| Q4 FY2024 | Dec 31, 2024 | $92.60B | -2.7% |
| Q3 FY2024 | Sep 30, 2024 | $93.67B | +2.6% |
| Q2 FY2024 | Jun 30, 2024 | $94.65B | +1.2% |
| Q1 FY2024 | Mar 31, 2024 | $99.03B | +5.0% |
| Q4 FY2023 | Dec 31, 2023 | $95.16B | -1.7% |
| Q3 FY2023 | Sep 30, 2023 | $91.26B | -7.1% |
| Q2 FY2023 | Jun 30, 2023 | $93.49B | -6.8% |
| Q1 FY2023 | Mar 31, 2023 | $94.28B | -8.5% |
| Q4 FY2022 | Dec 31, 2022 | $96.82B | -11.4% |
| Q3 FY2022 | Sep 30, 2022 | $98.20B | -11.4% |
| Q2 FY2022 | Jun 30, 2022 | $100.36B | -9.4% |
| Q1 FY2022 | Mar 31, 2022 | $103.03B | -8.4% |
| Q4 FY2021 | Dec 31, 2021 | $109.31B | -7.7% |
| Q3 FY2021 | Sep 30, 2021 | $110.89B | -11.7% |
| Q2 FY2021 | Jun 30, 2021 | $110.80B | -13.5% |
| Q1 FY2021 | Mar 31, 2021 | $112.44B | -13.0% |
| Q4 FY2020 | Dec 31, 2020 | $118.48B | -8.8% |
| Q3 FY2020 | Sep 30, 2020 | $125.54B | +118.6% |
| Q2 FY2020 | Jun 30, 2020 | $128.08B | +132.2% |
| Q1 FY2020 | Mar 31, 2020 | $129.29B | +271.1% |
| Q4 FY2019 | Dec 31, 2019 | $129.94B | +271.4% |
| Q3 FY2019 | Sep 30, 2019 | $57.43B | +70.3% |
| Q2 FY2019 | Jun 30, 2019 | $55.16B | +69.0% |
| Q1 FY2019 | Mar 31, 2019 | $34.83B | +5.3% |
| Q4 FY2018 | Dec 31, 2018 | $34.99B | +4.3% |
| Q3 FY2018 | Sep 30, 2018 | $33.73B | -0.7% |
| Q2 FY2018 | Jun 30, 2018 | $32.64B | -2.3% |
| Q1 FY2018 | Mar 31, 2018 | $33.08B | +0.4% |
| Q4 FY2017 | Dec 31, 2017 | $33.55B | -0.5% |
| Q3 FY2017 | Sep 30, 2017 | $33.98B | – |
| Q2 FY2017 | Jun 30, 2017 | $33.41B | – |
| Q1 FY2017 | Mar 31, 2017 | $32.94B | – |
| Q4 FY2016 | Dec 31, 2016 | $33.71B | – |
See a number that looks wrong?